SIR, The selection of drugs for clinical testing as 'slow acting' or 'disease modifying' agents in rheumatoid arthritis (RA) would be greatly facilitated if a suitable animal model was available as a screening test. Rat adjuvant arthritis has been tested in this regard and, despite some claims by others,' we have in this laboratory consistently failed to detect any inhibition of disease by drugs such as gold and penicillamine.23 These experiments have, however, involved administration of the drugs for only relatively short periods compared with the 3-6 months necessary to achieve a response in RA patients. For Within 3 days of starting the intramuscular injections rats in the high-dose group became obviously toxic, lost weight rapidly, and 50% died. However, the remainder of the group gradually recovered despite continuing to receive gold injections, and by 2 weeks these animals were gaining weight at the same rate as those in the other groups. This curious pattern of toxicity and 'tolerance' remains unexplained. We Our original hypothesis was that the increased prevalence of type 1 diabetes in close relatives of rheumatoid patients could be predicted from the association both these diseases have with HLA DR4. We mentioned in the concluding paragraph of our paper that we would like to study HLA genotypes in families where one sibling had rheumatoid arthritis and another sibling had type 1 diabetes or other autoimmune endocrine disease. Since our paper was published we have studied some of the original families reported and others not included in the study; we have also studied some patients with coexistent type 1 diabetes and rheumatoid arthritis. Although this work is at a preliminary stage there is no clear association between these two diseases and HLA DR4 in the families and individual patients studied.
The pedigrees of families with coexistent rheumatoid arthritis and type 1 diabetes suggest a relationship between these two diseases, and we are confident that a mechanism for the common genetic susceptibility will be identified. 
